Form 10-Q Sage Therapeutics, Inc. For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings
May 4, 2021 12:52 PM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $84.00 (from $89.00) while maintaining a Sector Perform rating following results.
The analyst commented, "This morning, SAGE reported 1Q21 earnings and guided for $1.7B in cash by end-'21, for a burn rate of... More
